Top stocks to buy at this time: Stock recommendations for March 12, 2025

Top stocks to buy (AI picture)

Stock market recommendations: According to Mehul Kothari, DVP – Technical Research, Anand Rathi Shares and Stock Brokers, Tube Investments, Godrej Agrovet Ltd, and Astrazeneca Pharma are the highest inventory picks for at this time:
TUBEINVEST: BUY Near ₹2850 | Stop Loss: ₹2600 | Target: ₹3350
The inventory was extremely oversold however has began to outperform in the previous couple of days. Most importantly, a change of development has been confirmed on the short-term charts. Today, a breakout was noticed with robust volumes, reinforcing the energy of this transfer.
Previously, a breakdown occurred round ₹3200–₹3300, and the inventory now seems to be making ready for a retest of that zone.
Thus, merchants are suggested to buy TUBEINVEST within the vary of ₹2750–₹2850, with a stop-loss at ₹2600 on a closing foundation, for an upside goal of ₹3350 within the coming 1–3 months.
GODREJAGRO: BUY ABOVE ₹750 | Stop Loss: ₹700 | Target: ₹850
The inventory has considerably outperformed the broader markets and has been consolidating in a variety for the previous 5–6 months. Based on the present construction, a breakout from this vary seems imminent.
With restricted draw back threat from present ranges, merchants are suggested to buy GODREJAGRO ABOVE ₹750, with a strict stop-loss at ₹700 on a closing foundation, for an upside goal of ₹850 within the coming 1–3 months.
ASTRAZEN: BUY Near ₹7800 | Stop Loss: ₹7500 | Target: ₹8400
The inventory displays a construction comparable to GODREJAGRO, however even stronger. Today, it delivered a significant vary breakout, and that too close to its lifetime excessive.
Additionally, RSI has confirmed a breakout, and ADX (14) crossing 28 alerts a strengthening development, indicating the potential for a pointy upside transfer.
Thus, merchants are suggested to buy ASTRAZEN within the vary of ₹7750–₹7850, with a stop-loss at ₹7500 on a closing foundation, for an upside goal of ₹8400 within the coming 1–3 months.
Disclaimer: The opinions, analyses and recommendations expressed herein are these of brokerage and don’t replicate the views of The Times of India. Always seek the advice of with a certified funding advisor or monetary planner earlier than making any funding choices.